NASDAQ:EYPTEyepoint Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Eyepoint Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.85 -0.03 (-3.35 %) (As of 05/28/2020 04:00 PM ET) Add Compare Share Today's Range$0.85Now: $0.85▼$0.9050-Day Range$0.76MA: $0.87▼$0.9852-Week Range$0.70Now: $0.85▼$2.69Volume232,631 shsAverage Volume673,109 shsMarket Capitalization$106.07 millionP/E RatioN/ADividend YieldN/ABeta1.42 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. The company also offers DEXYCU (dexamethasone intraocular suspension), an intraocular product for the treatment of postoperative ocular inflammation; and Vitrasert (ganciclovir), a sustained release implant for the treatment of cytomegalovirus retinitis. In addition, it develops YUTIQ shorter-acting uveitis for the treatment of NIPU; and Durasert tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration. Further, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, and Ocumension Therapeutics. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingEyepoint Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.63, Eyepoint Pharmaceuticals has a potential upside of 326.3% from its current price of $0.85.Amount of Analyst CoverageEyepoint Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesEyepoint Pharmaceuticals has received 397 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEyepoint Pharmaceuticals has received 326 “underperform” votes. (Add your “underperform” vote.)Community SentimentEyepoint Pharmaceuticals has received 54.91% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Eyepoint Pharmaceuticals and other stocks. Vote “Outperform” if you believe EYPT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EYPT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEyepoint Pharmaceuticals does not currently pay a dividend.Dividend GrowthEyepoint Pharmaceuticals does not have a long track record of dividend growth. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eyepoint Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $113,480.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders41.29% of the stock of Eyepoint Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.18% of the stock of Eyepoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Eyepoint Pharmaceuticals are expected to grow in the coming year, from ($0.35) to ($0.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eyepoint Pharmaceuticals is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eyepoint Pharmaceuticals is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyepoint Pharmaceuticals has a P/B Ratio of 6.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.32 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EYPT Previous Symbol CUSIPN/A CIK1314102 Webwww.eyepointpharma.com Phone617-926-5000Debt Debt-to-Equity Ratio3.06 Current Ratio4.83 Quick Ratio4.50Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$20.36 million Price / Sales5.21 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book6.54Profitability EPS (Most Recent Fiscal Year)($0.48) Net Income$-56,790,000.00 Net Margins-196.31% Return on Equity-286.40% Return on Assets-61.01%Miscellaneous Employees55 Outstanding Shares124,742,000Market Cap$106.07 million Next Earnings DateN/A OptionableOptionable NASDAQ:EYPT Rates by TradingView Receive EYPT News and Ratings via Email Sign-up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Eyepoint Pharmaceuticals (NASDAQ:EYPT) Frequently Asked Questions How has Eyepoint Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Eyepoint Pharmaceuticals' stock was trading at $1.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EYPT shares have decreased by 19.0% and is now trading at $0.8503. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Eyepoint Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyepoint Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eyepoint Pharmaceuticals. How were Eyepoint Pharmaceuticals' earnings last quarter? Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) issued its earnings results on Wednesday, May, 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.01. The firm had revenue of $7.49 million for the quarter, compared to analyst estimates of $6.95 million. Eyepoint Pharmaceuticals had a negative return on equity of 286.40% and a negative net margin of 196.31%. View Eyepoint Pharmaceuticals' earnings history. What price target have analysts set for EYPT? 4 brokers have issued 12 month price targets for Eyepoint Pharmaceuticals' stock. Their forecasts range from $1.00 to $5.00. On average, they expect Eyepoint Pharmaceuticals' share price to reach $3.63 in the next year. This suggests a possible upside of 326.3% from the stock's current price. View analysts' price targets for Eyepoint Pharmaceuticals. Has Eyepoint Pharmaceuticals been receiving favorable news coverage? News headlines about EYPT stock have been trending somewhat positive recently, InfoTrie reports. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Eyepoint Pharmaceuticals earned a daily sentiment score of 1.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutEyepoint Pharmaceuticals. Are investors shorting Eyepoint Pharmaceuticals? Eyepoint Pharmaceuticals saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 2,820,000 shares, a decline of 8.4% from the March 31st total of 3,080,000 shares. Based on an average daily trading volume, of 818,100 shares, the days-to-cover ratio is currently 3.4 days. Currently, 3.5% of the company's shares are short sold. View Eyepoint Pharmaceuticals' Current Options Chain. Who are some of Eyepoint Pharmaceuticals' key competitors? Some companies that are related to Eyepoint Pharmaceuticals include Fluidigm (FLDM), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Aethlon Medical (AEMD), Scientific Industries (SCND), Arrayit (ARYC), Precipio (PRPO), Pressure Biosciences (PBIO) and PositiveID (PSID). View all competitors. What other stocks do shareholders of Eyepoint Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eyepoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), XOMA (XOMA), Amarin (AMRN), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), Verastem (VSTM), AcelRx Pharmaceuticals (ACRX), Inovio Pharmaceuticals (INO), Catalyst Pharmaceuticals (CPRX) and Exelixis (EXEL). Who are Eyepoint Pharmaceuticals' key executives? Eyepoint Pharmaceuticals' management team includes the following people: Ms. Nancy S. Lurker, Pres, CEO & Director (Age 62)Mr. Leonard S. Ross, VP of Fin. & Chief Accounting Officer (Age 69)Dr. Dario A. Paggiarino, VP & Chief Medical Officer (Age 62)Mr. David J. Price, Chief Financial Officer (Age 56)Mr. Marty Nazzaro, Sr. VP of Operations What is Eyepoint Pharmaceuticals' stock symbol? Eyepoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT." Who are Eyepoint Pharmaceuticals' major shareholders? Eyepoint Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.06%), Franklin Resources Inc. (3.32%), State Street Corp (0.90%), Geode Capital Management LLC (0.72%), Essex Investment Management Co. LLC (0.51%) and Integrated Advisors Network LLC (0.38%). Company insiders that own Eyepoint Pharmaceuticals stock include Douglas Evan Godshall, Ew Healthcare Partners, LP, George Elston, Jay S Duker, John B Landis and Nancy Lurker. View institutional ownership trends for Eyepoint Pharmaceuticals. Which major investors are selling Eyepoint Pharmaceuticals stock? EYPT stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Essex Investment Management Co. LLC, and UBS Group AG. View insider buying and selling activity for Eyepoint Pharmaceuticals. Which major investors are buying Eyepoint Pharmaceuticals stock? EYPT stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Raymond James Financial Services Advisors Inc., Integrated Advisors Network LLC, Squarepoint Ops LLC, Geode Capital Management LLC, JPMorgan Chase & Co., Two Sigma Investments LP, and BlackRock Inc.. Company insiders that have bought Eyepoint Pharmaceuticals stock in the last two years include Douglas Evan Godshall, Ew Healthcare Partners, LP, George Elston, Jay S Duker, John B Landis, and Nancy Lurker. View insider buying and selling activity for Eyepoint Pharmaceuticals. How do I buy shares of Eyepoint Pharmaceuticals? Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Eyepoint Pharmaceuticals' stock price today? One share of EYPT stock can currently be purchased for approximately $0.85. How big of a company is Eyepoint Pharmaceuticals? Eyepoint Pharmaceuticals has a market capitalization of $106.07 million and generates $20.36 million in revenue each year. The company earns $-56,790,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. Eyepoint Pharmaceuticals employs 55 workers across the globe. What is Eyepoint Pharmaceuticals' official website? The official website for Eyepoint Pharmaceuticals is www.eyepointpharma.com. How can I contact Eyepoint Pharmaceuticals? Eyepoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company can be reached via phone at 617-926-5000 or via email at [email protected] This page was last updated on 5/28/2020 by MarketBeat.com Staff
